The Impact of Velcade(TM)on Antibody Secreting Cells in Sensitized Renal Allograft Candidates

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2014 by Mayo Clinic.
Recruitment status was  Active, not recruiting
Information provided by:
Mayo Clinic Identifier:
First received: July 23, 2008
Last updated: January 17, 2014
Last verified: January 2014
Patients planning to have kidney transplantation who are sensitized to their donors have high levels of donor specific alloantibodies. High levels of donor specific antibodies put kidney transplant recipients at risk for rejection very early after transplant. This study is trying to determine if the drug bortezomib (Velcade ™) can reduce donor specific alloantibodies to a level that permits kidney transplantation without a high risk for rejection.

Condition Intervention
Kidney Transplant
Drug: Bortezomib

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: The Impact of Velcade(TM)on Antibody Secreting Cells in Sensitized Renal Allograft Candidates

Resource links provided by NLM:

Further study details as provided by Mayo Clinic:

Primary Outcome Measures:
  • A 50% reduction in anti-HLA antibody production by bone marrow derived ASC isolated from sensitized renal allograft candidates treated with bortezomib monotherapy in vivo. [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 20
Study Start Date: June 2008
Estimated Study Completion Date: July 2015
Estimated Primary Completion Date: April 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Velcade Drug: Bortezomib
A minimum of four, four-dose cycles (16 doses) and up to eight, four-dose cycles(32 doses) of Velcade(TM) as an intravenous infusion (IV) (through a vein).
Other Name: Velcade(TM)

Detailed Description:
The study is designed to assess the impact of in vivo treatment of bortezomib on anti-HLA production by normal antibody secreting cells (ASC) in sensitized renal allograft candidates. The design involves in vivo treatment with bortezomib for one 4 dose cycle (days 1, 4, 8 and 11). Using novel assays, anti-HLA production is determined by bone marrow derived ASC at baseline (prior to therapy) and after treatment (at day 14, 3 days after the last bortezomib dose). Paired data are used with patients serving as their own controls. Finally, the safety of bortezomib is evaluated by monitoring total serum antibody levels and the incidence of side effects (primarily neuropathy) at 1 month, the final follow-up point.

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.

    • Female subject is post-menopausal, surgically sterilized, or she and/or sexual partner are willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study.
    • Male subject agrees to use an acceptable method for contraception for the duration of the study.
    • Renal transplant candidates who otherwise meet our acceptance criteria.
    • Evidence of alloantibody in their serum (panel reactive antibody >20% and specificities determined by single antigen flow bead assay.
    • Sensitized patients with no living donors or have donor-specific antibody levels too high to undergo successful transplantation using our current protocols (T or B cell crossmatch channel shift >500).

Exclusion Criteria:

  • Patient has a platelet count of <30 x 109/L within 14 days before enrollment.

    • Patient has an absolute neutrophil count of ANC<1.0 x 109/L within 14 days before enrollment.
    • Patient has >Grade 2 peripheral neuropathy within 14 days before enrollment.
    • Myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) Class III or IV heart failure (see section 8.4), uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any ECG abnormality at Screening has to be documented by the investigator as not medically relevant.
    • Patient has hypersensitivity to bortezomib, boron or mannitol.
    • Female subject is pregnant or breast-feeding. Confirmation that the subject is not pregnant must be established by a negative serum B-human chorionic gonadotropin (B-hCG) pregnancy test result obtained during screening. Pregnancy testing is not required for post-menopausal or surgically sterilized women.
    • Patient has received other investigational drugs within14 days before enrollment.
    • Serious medical or psychiatric illness likely to interfere with participation in this clinical study.
    • Diagnosed or treated for malignancy within 5 years of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy.
    • Contraindication to kidney transplantation—active infection, comorbid medical conditions, etc.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00722722

United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Mayo Clinic
Principal Investigator: Mark D. Stegall, M.D. Mayo Clinic
  More Information

Additional Information:
Responsible Party: Mark Stegall, M.D., Mayo Clinic Identifier: NCT00722722     History of Changes
Other Study ID Numbers: 08-000556 
Study First Received: July 23, 2008
Last Updated: January 17, 2014
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Antineoplastic Agents
Pharmacologic Actions
Therapeutic Uses processed this record on May 03, 2016